Targeted synthesis of a series of 4-o-aryl- and 4-N-alkyl/arylquinazolines for stu-dying the JNK-kinase activity

Authors

  • I. Yu. Kapustyansky National University of Pharmacy, Ukraine
  • S. M. Kovalenko National University of Pharmacy, Ukraine
  • L. V. Yevsieieva National University of Pharmacy, Ukraine
  • O. V. Zaremba National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.24959/ophcj.14.792

Keywords:

4-O-aryl- and 4-N-alkyl(aryl)quinazolines, 4-N-(cyanoaryl)quinazolines, JNK-kinase inhibitors

Abstract

To study the JNK-kinase activity of quinazoline derivatives a series of 4-O-aryl- and 4-N-alkylquinazolines have been synthesized in standard condition of nucleophilic substitution of 4-chloroquinazolines in the presence of potassium carbonate. 4-Chloroquinazolines have been obtained by the reaction of POCl3 with 3H-quinazolin-4-оnes using DMFA as a solvent. The abovementioned conditions have not yielded the desired results for the synthesis of 4-N-arylquinazolines, so acetic acid is used for the reaction catalysis. Therefore, 40 compounds of 4-(O)N-(aryl) alkylquinazolines class have been obtained. The structures of the compounds synthesized have been confirmed by NMR 1H-spectroscopy data. Characteristic signals of quinazoline protons in the second position are observed in the spectra of the compounds obtained. The signals of other protons are in good correlation with the expected structures. The melting points and purity of the compounds synthesized have been also determined. Using the PASS Professional programme the computer prediction of the biological activity of the compounds synthesized has been conducted; according to its results the compounds with the potential kinase activity have been selected. They are 4-N-arylquinazolines. The biological examination have been conducted under conditions in vitro in the culture medium of hepatocytes. The impact of substances on the activity of alanine aminotransferase has been determined and the activity of 4-N-(cyanoaryl)quinazolines as JNK-kinase inhibitors has been confirmed.

Downloads

Download data is not yet available.

References

  1. Barker A.J. Quinazoline derivatives. EP 0566226 A1, 20.10.1993.
  2. Barker A.J., Brown D.S. Quinazoline derivatives. EP 0602851 A1, 22.06.1994.
  3. Barker A.J., Davies D.H. Therapeutic Preparations Containing Quinazoline Derivatives. ЕР 0520722 А1, 30.12.1992.
  4. Scheiner P., Frank L., Giusti I., Arwin S., Pearson S.A. J. Heterocycl. Chem., 1984, Vol. 21, рр.1817-1824.
  5. Tobe M., Isobe Y., Tomizawa H., Nagasaki T., Takahashi H., Hayashi H. Bioorg. Med. Chem., 2003, Vol. 11, No.3, рр.383-392.
  6. Tobe M., Isobe Y., Tomizawa H., Matsumoto M., Obara F., Nagasaki T., Hayashi H. Bioorg. Med. Chem. Lett., 2001, Vol. 11, No.4, рр.545-548.
  7. Tobe M., Isobe Y., Tomizawa H., Nagasaki T., Takahashi H., Hayashi H. Bioorg. Med. Chem., 2003, Vol. 11, No.18, рр. 3869-3878.
  8. Tobe M., Isobe Y., Tomizawa H., Nagasaki T., Obara F., Hayashi H. Bioorg. Med. Chem., 2003, Vol. 11, No.4, рр.609-616.
  9. Holladay M.W., Campbell B.T., Rowbottom M.W., Chao Q., Sprankle K.G., Lai A.G., Abraham S., Faraoni R., Tran L., Armstrong R.C., Gunawardane R.N., Gardner M.F., Cramer M.D., Gitnick D., Bhagwat S.S., James J., Setti E., Ator M.A., Dorsey B.D., Ruggeri B.R., Williams M. Bioorg. Med. Chem. Lett., 2011, Vol. 21, No.18, рр.5342-5346.
  10. Rowbottom M.W., Faraoni R., Chao Q., Campbell B.T., Lai A.G., Setti E., Ezawa M., Sprankle K.G., Abraham S., Tran L., Struss B., Gibney M., Armstrong R.C., Gunawardane R.N., Nepomuceno R.R., Valenta I., Hua H., Gardner M.F., Cramer M.D., Gitnick D., Insko D.E., Apuy J.L., Bhagwat S., James J., Holladay M.W., Jones-Bolin S., Ghose A.K., Herbertz T., Ator M.A., Dorsey B.D., Ruggeri B., Williams M. J. Med. Chem., 2012, Vol. 55, No.3, рр.1082-1105.
  11. Potashman M.H., Bready J., Coxon A., DeMelfi T.M., DiPietro L., Doerr N., Elbaum D., Estrada J., Gallant P., Germain J., Gu Y. J. Med. Chem., 2007, Vol. 50, No.18, рр.4351-4373.
  12. Ple P.A., Jung F., Hennequin L., Morgentin R., Pasquet G., Ashton S., Laine R., Taylor S. Bioorg. Med. Chem. Lett., 2012, Vol. 22, No.1, рр.262-266.
  13. Shallal H.M., Russu W.A. Eur. J. Med. Chem., 2011, Vol. 46, No.6, рр.2043-2057.
  14. Saari R., Toermae J.-C., Nevalainen T. Bioorg. Med. Chem., 2011, Vol. 19, No.2, рр.939-950.
  15. Shen Z.-L., He X.-F., Hong Y.-M., Hu X.-Q., Mo W.-M., Hu B.-X., Sun N. Synthetic Communications, 2011, Vol. 41, No.24, рр.3644-3653.

Downloads

Published

2014-06-10

How to Cite

(1)
Kapustyansky, I. Y.; Kovalenko, S. M.; Yevsieieva, L. V.; Zaremba, O. V. Targeted Synthesis of a Series of 4-O-Aryl- and 4-N-alkyl/Arylquinazolines for Stu-Dying the JNK-Kinase Activity. J. Org. Pharm. Chem. 2014, 12, 70-75.

Issue

Vol. 12 No. 2(46) (2014)

Section

Original Researches

License

Copyright (c) 2014 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors publishing their works in the Journal of Organic and Pharmaceutical Chemistry agree with the following terms:

1. Authors retain copyright and grant the journal the right of the first publication of the work under Creative Commons Attribution License allowing everyone to distribute and re-use the published material if proper citation of the original publication is given.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book) providing proper citation of the original publication.

3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on authors’ personal websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).